Tech Center 1600 • Art Units: 1637 1683
This examiner grants 29% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17864930 | DECENTRALIZED WORKFLOWS FOR SINGLE CELL ANALYSIS | Final Rejection | ILLUMINA, INC. |
| 18008989 | COMPOSITIONS AND METHODS FOR DNA METHYLATION ANALYSIS | Final Rejection | President and Fellows of Harvard College |
| 18163819 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR LYMPHOMA | Non-Final OA | Genentech, Inc. |
| 18300814 | METHODS AND COMPOSITIONS FOR PROBE DETECTION AND READOUT SIGNAL GENERATION | Final Rejection | 10x Genomics, Inc. |
| 17801078 | METHODS TO COMBINE FIRST AND SECOND STRAND cDNA SYNTHESIS FOR SPATIAL ANALYSIS | Non-Final OA | 10x Genomics, Inc. |
| 18564478 | MASSIVE GENERATION OF CHEMICALLY LIGATEABLE PROBES FOR MULTIPLEXED FISH | Non-Final OA | CALIFORNIA INSTITUTE OF TECHNOLOGY |
| 17634908 | CONTROLLING THE DNA HYBRIDIZATION CHAIN REACTION | Final Rejection | NORTHWESTERN UNIVERSITY |
| 18157587 | Methods Of Improving Health With Apolipoprotein E (APOE) Inhibitors | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18264741 | A CONTINUOUS METRIC TO MEASURE ENDOTYPE AND CORTICOSTEROID INTERACTION IN SEPTIC SHOCK | Non-Final OA | VANDERBILT UNIVERSITY |
| 18324828 | L-DNA ENCRYPTED TRACERS | Non-Final OA | Vanderbilt University |
| 17484067 | ENGINEERED MULTI-OMIC DISPLAY CONSTRUCTS AND DISPLAY SYSTEMS | Final Rejection | Massachusetts Institute of Technology |
| 17629571 | METHODS FOR DETERMINING RISK OF DEVELOPING INSULIN RESISTANCE | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18926340 | GENE SEQUENCING METHOD | Non-Final OA | SHENZHEN SALUS BIOMED CO., LTD |
| 17642640 | DETECTION OF CIRCULATING TUMOR DNA USING DOUBLE STRANDED HYBRID CAPTURE | Non-Final OA | UNIVERSITY HEALTH NETWORK |
| 17907482 | Compositions and Methods for Detecting Molecular Targets on Chromosomal DNA | Non-Final OA | New England Biolabs, Inc. |
| 17771591 | COLOR AND BARCODED BEADS FOR SINGLE CELL INDEXING | Non-Final OA | Miltenyi Biotec B.V. & Co. KG |
| 17995323 | A METHOD OF DETECTING STRUCTURAL REARRANGEMENTS IN A GENOME | Non-Final OA | Roche Sequencing Solutions, Inc. |
| 18352040 | COMPOSITIONS AND METHODS TARGETING S100A10 FOR THE TREATMENT AND DIAGNOSIS OF LIVER CANCER | Non-Final OA | The University of Hong Kong |
| 17921582 | PSEUDO-COMPLEMENTARY BASES IN GENOTYPING AND NUCLEIC ACID SEQUENCING | Final Rejection | Cepheid |
| 18195049 | HIGH THROUGHPUT SINGLE CELL BASED ASSAY FOR CAPTURING GENOMIC INFORMATION FOR FUNCTIONAL AND IMAGING ANALYSIS AND METHODS OF USE | Non-Final OA | Zafrens, Inc. |
| 17740072 | DNA AMPLIFICATION BUFFER REPLENISHMENT DURING ROLLING CIRCLE AMPLIFICATION | Non-Final OA | Pacific Biosciences of California, Inc. |
| 17702708 | FRAGMENT ANALYSIS FOR QUANTITATIVE DIAGNOSTICS OF BIOLOGICAL TARGETS | Non-Final OA | BillionToOne, Inc. |
| 17641048 | METHOD FOR SEQUENCING RNA OLIGONUCLEOTIDES | Non-Final OA | CeMM - Forschungszentrum für Molekulare Medizin GmbH |
| 17744231 | METHODS FOR DISEASE DETECTION | Non-Final OA | Universal Diagnostics, S.A. |
| 17063136 | DNA-METHYLATION TEST FOR PROSTATE CANCER | Final Rejection | UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN |
| 18204037 | ELECTROPHORESIS-MEDIATED CHARACTERIZATION OF DNA CONTENT OF ADENO-ASSOCIATED VIRUS CAPSIDS | Non-Final OA | PerkinElmer Health Sciences, Inc. |
| 17768601 | COMPOSITION FOR DIAGNOSING LIVER CANCER BY USING CPG METHYLATION CHANGES IN SPECIFIC GENES, AND USE THEREOF | Final Rejection | GENCURIX INC. |
| 17799496 | NUCLEIC ACID CONSTRUCT, AND THERAPEUTIC OR DIAGNOSTIC AGENT FOR MISMATCH REPAIR DEFICIENT CANCERS COMPRISING NUCLEIC ACID CONSTRUCT | Non-Final OA | PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY |
| 17661813 | SYSTEMS, METHODS, AND APPARATUS FOR AUTOMATED SELF-CONTAINED BIOLOGICAL ANALYSIS | Final Rejection | Co-Diagnostics, Inc. |
| 17631558 | MULTIPLEX LIGATION-DEPENDENT PROBE MICROARRAY DETECTION | Non-Final OA | FLASHDX SHENZHEN INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy